Table 1 Demographics, clinical characteristics, serological and arterial biophysical parameters of patients with SLE and healthy controls.
SLE patients, (n = 71) | Healthy controls, (n = 71) | P value | |
|---|---|---|---|
Mean ± SD; number (%) | |||
Age, years | 39.21 ± 13.4 | 40.37 ± 12.9 | — |
Gender, female | 65 (91.5) | 65 (91.5) | — |
Body mass index, kg/m2 | 22.54 ± 5.1 | 22.86 ± 4.2 | 0.834 |
Systolic blood pressure, mmHg | 122.98 ± 20.6 | 117.53 ± 15.1 | 0.076 |
Diastolic blood pressure, mmHg | 73.31 ± 11.9 | 70.52 ± 10.0 | 0.133 |
Atherogenic index* | 3.09 ± 1.6 | 3.21 ± 1.4 | 0.611 |
Cumulative clinical manifestation | |||
Malar rash | 38 (53.5) | — | — |
Discoid | 3 (4.2) | — | — |
Photosensitivity | 21 (29.6) | — | — |
Mucocutaneous ulcers | 13 (18.3) | — | — |
Arthritis | 40 (56.3) | — | — |
Serositis | 7 (9.9) | — | — |
Renal | 21 (29.6) | — | — |
Neurological | 9 (12.7) | — | — |
Haematological | 32 (45.1) | — | — |
Leucopenia | 18 (25.4) | — | — |
Thrombocytopenia | 9 (12.7) | — | — |
Anaemia | 26 (36.6) | — | — |
Haemolytic anaemia | 8 (11.3) | — | — |
Serology | |||
ANA positivity | 70 (98.6) | — | — |
C3, mg/dL | 78.73 ± 32.4 | — | — |
C4, mg/dL | 15.16 ± 11.5 | — | — |
Anti-dsDNA, IU/ml | 100.36 ± 88.1 | — | — |
Duration of disease, months | 43.85 ± 62.1 | — | — |
Prednisolone dose, mg/day | 13.43 ± 14.4 | — | — |
SLEDAI | 6.52 ± 5.4 | — | — |
SLICC/ACR DI | 0.17 ± 0.4 | — | — |
Arterial biophysical parameters | |||
baED-FMD, % | 3.72 ± 2.8 | 4.63 ± 3.1 | 0.032 |
cIMT, mm | 0.56 ± 0.1 | 0.56 ± 0.1 | 0.872 |
aFABP, ng/ml | 14.82 ± 3.3 | 13.69 ± 4.6 | 0.015 |
